In addition, another antidiabetic drug sodium-glucose-cotransporter-2 (SGLT-2) inhibitors can improve metabolic parameters and cardiovascular risk in patients with or without diabetes in pre-clinical and clinical studies (13, 14, 14, 15). The gene discussed is SLC5A2; the disease is diabetes mellitus.